Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
暂无分享,去创建一个
Á. Avezum | B. Lewis | R. Diaz | J. Healey | S. Connolly | S. Hohnloser | J. Eikelboom | R. Hart | T. Vanassche | M. Alings | John W Eikelboom | Marco Alings | Stuart J Connolly | Robert G Hart | O. Shestakovska | Basil S Lewis | Alvaro Avezum | Stefan H Hohnloser | Jeff S Healey | Thomas Vanassche | Mandy N Lauw | Rafael Díaz | Olga Shestakovska | Jia Wang | Jia Wang | M. Lauw
[1] Deepak K Gupta,et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. , 2014, European heart journal.
[2] P. Petersen,et al. Embolic complications in paroxysmal atrial fibrillation. , 1986, Stroke.
[3] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[4] W. Kannel,et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.
[5] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[6] Salim Yusuf,et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. , 2012, Journal of the American College of Cardiology.
[7] G. Lip,et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.
[8] K. Flegel,et al. Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. , 1989, Stroke.
[9] Bernard Rosner,et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.
[10] L. Moroni,et al. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial , 2013, BMC Cardiovascular Disorders.
[11] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[12] Daniel Levy,et al. Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .
[13] L. Frison,et al. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation , 2008, Journal of internal medicine.
[14] The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. , 1997, Archives of internal medicine.
[15] Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.
[16] R McBride,et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.
[17] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[18] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[19] S. Yusuf,et al. Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy , 2012, Circulation.
[20] F. Humar,et al. Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. , 1999, American heart journal.
[21] G. Lip,et al. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. , 1996, American heart journal.
[22] M. Rosenqvist,et al. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. , 2010, European heart journal.
[23] J. Halperin,et al. Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.
[24] A. Banerjee,et al. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. , 2012, International journal of cardiology.
[25] D. Fatkin,et al. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. , 1994, Journal of the American College of Cardiology.
[26] S. Yusuf,et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. , 2010, American heart journal.
[27] Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[28] Robby Nieuwlaat,et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. , 2010, Journal of the American College of Cardiology.
[29] J. Le Heuzey,et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. , 2006, American heart journal.
[30] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[31] B. Gersh,et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. , 2013, European heart journal.
[32] Denis Roy,et al. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. , 1986, American heart journal.
[33] Habib Gamra,et al. Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.
[34] M. Pathy,et al. Atrial fibrillation and stroke in elderly hospitalized patients. , 1986, Age and ageing.
[35] J. Halperin,et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.
[36] M. Wallander,et al. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. , 2009, International journal of cardiology.
[37] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[38] C. Granger,et al. Biomarkers in atrial fibrillation: a clinical review. , 2013, European heart journal.
[39] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[40] Salim Yusuf,et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. , 2007, Journal of the American College of Cardiology.
[41] P. Platonov,et al. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. , 2011, Journal of the American College of Cardiology.
[42] A. Capucci,et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? , 2008, European heart journal.